News | May 20, 2011

European Registry of 2,300 Transcatheter Valve Patients Shows Good One-Year Outcomes

May 20, 2011 - Edwards Lifesciences Corporation announced that clinicians continued to achieve successful one-year outcomes in high-risk or inoperable patients undergoing transcatheter aortic valve replacement during the first two years of commercialization of the Edwards Sapien valve. Data on the more than 2,300 patients enrolled in the post-market European SOURCE Registry since November 2007 were presented in a late-breaking clinical trial session today at EuroPCR 2011.

Despite high predicted mortality and multiple co-morbidities in many of these patients, survival at one year was 76 percent in the 1,038 patients treated as part of Cohort I (first year of commercialization), and 77 percent in the 1,269 patients treated as part of Cohort II (second year of commercialization). For all of the patients in both cohorts, the one-year survival for those receiving transfemoral valve replacement (via the femoral artery), was 80.1 percent, and for transapical patients (via a small incision between the ribs), it was 74.2 percent.

The SOURCE Registry includes data from patients treated with the Edwards SAPIEN transcatheter heart valve at 32 European centers in its initial Cohort I, and 37 centers in Cohort II. One year follow-up data were obtained on 98 percent of patients. This is the largest reported experience in the world with data on consecutive patients within each hospital who were treated with transcatheter heart valves delivered transfemorally or transapically. In Cohort I, there were 463 transfemoral and 575 transapical procedures; in Cohort II, there were 457 transfemoral and 812 transapical procedures. The principal investigators of the SOURCE Registry are Olaf Wendler, M.D., Ph.D., clinical director for cardiology and cardiothoracic surgery, King's College Hospital, and Martyn Thomas, M.D., clinical director for cardiothoracics, Guy's and St. Thomas' NHS Foundation Trust.

Also today at EuroPCR, Edwards announced the receipt of CE Mark approval for sale in the European Union of the NovaFlex+ transfemoral delivery system for use with the next-generation Edwards SAPIEN XT transcatheter heart valve. This new system incorporates modifications focused on improving ease of use and is designed to make valve alignment prior to deployment more reliable. Edwards is launching this system, as well as the eSheath expandable sheath technology, at EuroPCR. The eSheath, which received CE Mark earlier this year, enables the use of a low profile sheath and is designed to reduce vascular complications. The Edwards SAPIEN valve, Edwards SAPIEN XT valve, NovaFlex+ and eSheath are investigational devices not yet available commercially in the United States.

For more information: www.edwards.com

Related Content

Pregnancy-Related Heart Failure Strikes Black Women Twice as Often as Other Races
News | Womens Healthcare| October 19, 2017
African American women were found to be twice as likely to be diagnosed with peripartum cardiomyopathy as compared to...
MRI May Predict Neurological Outcomes for Cardiac Arrest Survivors
News | Sudden Cardiac Arrest| October 18, 2017
Magnetic resonance imaging (MRI)-based measurements of the functional connections in the brain can help predict long-...
Xarelto Significantly Reduces Major Cardioavascular Events in Stable CAD and PAD Patients
News | Pharmaceuticals| October 18, 2017
October 18, 2017 — Results from the pivotal Phase 3 COMPASS study found that the...
First Patient Enrolled in U.S. Arm of ALIVE Pivotal Heart Failure Trial
News | Heart Failure| October 17, 2017
October 17, 2017 — BioVentrix Inc. recently announced enrollment of the first patient in the U.S.
Appropriate Use Criteria Published for Valvular Heart Disease Imaging Tests
News | Clinical Decision Support| October 16, 2017
The American College of Cardiology (ACC), along with several partnering societies, recently released appropriate use...
Low Mortality and Stroke Risks Displayed for Minimally Invasive Aortic Valve Replacements
News | Heart Valve Technology| October 11, 2017
An analysis of more than 1,000 minimally invasive aortic valve replacements and more than 400 additional associated...
New Evaluation Sends Low-Risk ER Chest Pain Patients Home Sooner
News | Cardiac Diagnostics| October 10, 2017
A new evaluation to determine whether emergency room patients with chest pain can go home and follow up with their...
News | Pharmaceuticals| October 04, 2017
October 4, 2017 — MyoKardia Inc.
Medtronic Announces Post-Market Study for CoreValve Evolut Pro System
News | Heart Valve Technology| October 02, 2017
Medtronic plc recently announced a new post-market clinical study to evaluate its CoreValve Evolut Pro valve in...
BioCardia Announces 12-Month Results from TRIDENT Trial of Stem Cell Delivery System
News | Stem Cell Therapies| September 26, 2017
BioCardia Inc. recently announced 12-month results from the Phase II TRIDENT clinical trial, conducted by the...
Overlay Init